Literature DB >> 21777743

Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure.

Micha T Maeder1, Ouda Khammy, Cris dos Remedios, David M Kaye.   

Abstract

OBJECTIVES: This study sought to determine the potential pathophysiological link between anemia and disease severity, and adverse outcome in heart failure (HF).
BACKGROUND: Anemia frequently accompanies advanced HF; however, the pathophysiological mechanism responsible for the association between anemia and more severe HF remains uncertain. We hypothesized that a depletion of myocardial iron content may provide the biological link.
METHODS: Complementary clinical and basic studies were performed. Hemodynamic, biochemical, and echocardiographic investigations were performed in 9 healthy controls and 25 patients with advanced HF (left ventricular ejection fraction: 23 ± 10%). Tissue iron content and type 1 transferrin receptor (Tfr1) expression were assessed in human myocardial tissue, and the regulation of Tfr1 expression was studied in isolated cardiomyocytes.
RESULTS: HF patients displayed evidence of iron deficiency as measured by lower serum iron (p < 0.05) and transferrin saturation (TFS) (p < 0.05). When subclassified according to the presence of anemia, TFS was lower in anemic compared with nonanemic HF patients, whereas TFS in nonanemic HF patients was intermediate. In association, myocardial iron content was reduced in HF versus non-HF samples (0.49 ± 0.07 μg/g vs. 0.58 ± 0.09 μg/g, p < 0.05), and there was a significant reduction (p < 0.05) in the myocardial mRNA expression of Tfr1, which plays a key role in cellular iron transport. In the context of HF, catecholamines and aldosterone both down-regulated Tfr1 expression in isolated cardiomyocytes.
CONCLUSIONS: This study suggests the presence of iron depletion in the failing human heart, providing a potential link for the association between anemia and adverse prognosis in HF.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777743     DOI: 10.1016/j.jacc.2011.01.059

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  44 in total

1.  The role of iron, omega-3 Fatty acids, and vitamins in heart failure.

Authors:  Donald S Silverberg; Doron Schwartz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 2.  Iron deficiency as therapeutic target in heart failure: a translational approach.

Authors:  Constantinos Bakogiannis; Alexandros Briasoulis; Dimitrios Mouselimis; Anastasios Tsarouchas; Nikolaos Papageorgiou; Christodoulos Papadopoulos; Nikolaos Fragakis; Vassilios Vassilikos
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 3.  Old and new tools to assess dyspnea in the hospitalized patient.

Authors:  Barbro Kjellström; Martje H L van der Wal
Journal:  Curr Heart Fail Rep       Date:  2013-09

4.  Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.

Authors:  Pavel Zhabyeyev; Gavin Y Oudit
Journal:  Eur Heart J       Date:  2017-02-01       Impact factor: 29.983

Review 5.  Iron in kidney and heart failure: from theory to practice.

Authors:  Aslihan Yerlikaya; Mustafa C Bulbul; Baris Afsar; Tuncay Dagel; Gamze Aslan; Luminita Voroneanu; Dimitire Siriopol; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2017-09-22       Impact factor: 2.370

6.  [Heart failure and anemia].

Authors:  S Reda; L J Motloch; U C Hoppe
Journal:  Herz       Date:  2013-09       Impact factor: 1.443

7.  Is cardiac and hepatic iron status assessed by MRI T2* associated with left ventricular function in patients with idiopathic cardiomyopathy?

Authors:  Yumiko Kanzaki; Masako Yuki; Ken-Ichiro Yamamura; Yoshifumi Narumi; Nobukazu Ishizaka
Journal:  Heart Vessels       Date:  2016-02-20       Impact factor: 2.037

Review 8.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

Authors:  Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske
Journal:  Eur Heart J       Date:  2014-08-07       Impact factor: 29.983

9.  Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure.

Authors:  Gregory D Lewis; Marc J Semigran; Michael M Givertz; Rajeev Malhotra; Kevin J Anstrom; Adrian F Hernandez; Monica R Shah; Eugene Braunwald
Journal:  Circ Heart Fail       Date:  2016-05       Impact factor: 8.790

10.  Heme levels are increased in human failing hearts.

Authors:  Arineh Khechaduri; Marina Bayeva; Hsiang-Chun Chang; Hossein Ardehali
Journal:  J Am Coll Cardiol       Date:  2013-03-06       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.